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So far, we know that no biofortified (genetically modi-
fied/engineered, GM) rice has been grown commer-
cially. Several confined field trials of first- and second-
generation GM rice1 have been conducted in many
countries by the International Rice Research Institute
(IRRI) and its associated partner institutes. Some of this
GM rice is waiting for its regulation and commercializa-
tion (Demont, Chen, Ye, & Stein, 2013, cited in Demont
& Stein, 2013). Nonetheless, regulators have approved
GM rice for commercialization (Pritchard, Ortiz, &
Shekar, 2016; Sui et al., 2017). It is likely that GM rice
will be commercialized soon, but it might take a while
because domestic regulatory approval is a lengthy pro-
cess and/or regulators might simply delay the decision
of approval while acquiring new information. For exam-
ple, Golden rice (Vitamin-A-enriched GM rice) was
expected to be commercially available first in 2002, but
Bangladeshi and Indian regulators have yet to approve it
(Wesseler & Zilberman, 2014). In China, two insect-
resistant GM rice lines were granted biosafety certifi-
cates after 10 years of comprehensive biosafety assess-
ment (Lu, 2016), but are yet to be cultivated
commercially.
Even though the estimated annual benefits from the
first- and second-generation GM rice developed thus far
could be $64 billion USD2 globally (Demont & Stein,
2013), regulators may be cautious of its approval and
may not want to be a first-mover. This may be because
of precautionary risks of GM rice for human and envi-
ronmental health and anti-GM worries. And, thus, there
is a cost of delaying the regulatory approval and subse-
quent commercialization. Because of delaying commer-
cialization of a GM crop, the forgone welfare benefits
could be hundreds of millions of dollars (Smyth & Phil-
lips, 2002, and Pray, Bengali, & Ramaswami, 2005,
cited in Smyth, Kerr, & Phillips, 2017). In the case of
Golden rice, Wesseler and Zilberman (2014) estimated
that a forgone benefit of 10-year delay in the introduc-
tion could be between $0.71 and $2.83 billion (com-
pounded net present value). It could be $199 million
1. GM rice can be categorized as (i) first-generation GM rice, 
which is focused mainly on farmers’ benefits, e.g., herbicide-
tolerant, insect-resistant, drought-tolerant, drought- and 
salinity-tolerant (DST), and submergence-tolerant (Sub1). 
The main focus was to increase yields, improve resistance to 
biotic and abiotic stresses, and lower the cost of rice produc-
tion; (ii) second-generation GM rice is focused on consumer 
benefits, i.e., nutritionally enriched rice (Golden rice, folate-
rice, multi-biofortified rice; Anderson, Jackson, & Nielsen, 
2004; Demont & Stein, 2013); and (iii) third-generation GM 
rice, which is focused on farmers’ benefits under extreme cli-
matic stress conditions, i.e., C4 rice, which is expected to yield 
more under high temperature with less nitrogen and less 
water than the current rice.
2. All figures in this paper are in US dollars unless otherwise 
noted.
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So far, most new biotech crops have been developed by trans-
forming one or two genes with preferred traits. Compliance
costs for regulatory approval of this type of crop vary among
countries and according to whether the new biotech crop is a
food or non-food crop. However, whether a new biotech crop
with multiple transformed genes would cost significantly more
and take much more time to be approved is unknown. This
paper estimates the compliance costs for the regulatory
approval of C4 rice, a new GM rice plant required several gene
transformations, assuming it would be realized simultaneously
in the 13 Asian countries in 2035. We found it to be $18.8 million
(undiscounted), around 16.3% of the total research and devel-
opment (R&D) costs. We also estimated the present value of
R&D costs for C4 rice in 2017 prices to be approximately $106
million. These estimated R&D costs could be useful to quantity
the net welfare benefits from the introduction of C4 rice. In addi-
tion, donors could use this result as a guideline to fund addi-
tional investment required to develop C4 rice.
Key words: Asia, biofortified, biosafety, C4 rice, compliance 
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regulatory approval of C4 rice, a multi-gene engineered
rice, could be delayed similar to Golden rice. However,
if the introduction of Golden rice will have not found
any potential heath and ecological risks, commercializa-
tion of C4 rice could be faster.
Most new biotech crops, including first- and second-
generation GM rice, have been developed by transform-
ing one or two genes with preferred traits. Compliance
costs for regulatory approval of this type of crop vary
among countries and according to whether the new bio-
tech crop is a food or non-food crop (Smyth et al.,
2017). However, whether a new biotech crop with mul-
tiple transformed genes would cost significantly more
and take much more time to be approved is unknown. In
this article, we quantified the domestic regulatory
approval costs of C4 rice, a third-generation GM rice
under development, assumed to be commercialized in
2035 and adopted by the major rice-producing and -con-
suming countries in Asia. The regulatory approval of
this new GM rice could be challenging because it would
be engineered with several required traits. Because of
the nature of C4 rice, the costs of compliance for regula-
tory approval could be enormous and take much more
time. However, the hope is that, if other GM rice already
developed and waiting for regulation and commercial-
ization (e.g., Golden rice) becomes approved before the
introduction of C4 rice, then approval of this new rice
could be easier and less costly. Considering the worst-
case scenario, we estimated that the domestic regulatory
cost of C4 rice to be adopted by 13 Asian countries3
could be up to $18.8 million, if the country’s public
organization files for approval.
History and Development of C4 Rice
The idea behind developing a C4 rice plant is to save the
world, providing enough food for the more than 9 bil-
lion people projected for 2050, for their food and nutri-
tional security that the current rice, a C3 plant, is
unlikely to secure under the pressure of high population
growth and extreme climate change scenarios. John
Sheehy, a plant physiologist at IRRI, was the first one
who conceived the C4 Rice Project.4 The goal of this
project was to improve photosynthetic efficiency in rice
by introducing a two-celled C4 cycle and thus increase
rice yield. In other words, the goal was to create a new
rice plant (C4 rice) close to a plant that uses C4 photo-
synthesis.5 For example, maize, sugarcane, and sorghum
plants use C4 photosynthesis, whereas rice plants use C3
photosynthesis. In 1999, John Sheehy invited world-
renowned rice scientists to attend a workshop to discuss
the feasibility of this project. Unfortunately, the work-
shop concluded that it was unfeasible at that moment
because of the unavailability of methods and technology
required to deliver the scientific objectives (Sheehy,
Mitchell, & Hardy, 2000). However, in 2006, he orga-
nized another workshop to discuss the evaluation of the
new pathways to C4 rice and he gained momentum for
his idea (Sheehy et al., 2007). In 2008, to invent C4 rice,
an international C4 rice consortium was formed at IRRI
with funds from the Bill & Melinda Gates Foundation
(BMGF). At that time, several other world-renowned
organizations, including the University of Cambridge,
University of Oxford, University of Minnesota, Austra-
lian National University, and University of Toronto,
partnered with IRRI to realize the project.
To develop C4 rice, a total of 13 genes would be
engineered into C3 rice (Quick, 2012). The development
phases of the C4 rice plant were divided into four: (i)
gene discovery and molecular toolbox, and characterize
regulatory controls; (ii) transform rice to express Kranz
anatomy and the C4 metabolic enzymes; (iii) optimize
C4 function in transgenic rice; and (iv) breed C4 from
transgenics into local varieties (IRRI, 2012, and Table
1). Initially, the project life-span was considered to be
15 years, which started in October 2008. This project
already successfully finished the first two phases,
although the second phase had a one-year lag in the ini-
tial time-span. Currently, the project has entered into its
third phase of plant development (Roeber & Bernds,
2015), and the final development stage is expected to be
finished by 2023 (Column 2 in Table 1).
C4 Rice for Future Global Food Security
Rice is the staple food for more than one-half of the
world’s population (Islam, Rahman, Islam, & Naidu,
2016; Muthayya, Sugimoto, Montgomery, & Maberly,
2014), and is considered a basic source of calorie and
protein intake. Currently, approximately 470 million
metric tons of milled rice are produced annually in the
3. Bangladesh, Cambodia, China, India, Nepal, Pakistan, Sri 
Lanka, Indonesia, Malaysia, Myanmar, the Philippines, Thai-
land, and Vietnam.
4. A detailed description about this project can be found at 
https://c4rice.com/the-project-2/.
5. This idea of C4 photosynthesis is not new; it was discovered 
more than one-half century ago (a detailed review can be 
found in Furbank, 2016).Bairagi & Mohanty — Compliance Costs for Regulatory Approval of C4 Rice
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Asia (US Department of Agriculture [USDA], Foreign
Agricultural Service [FAS], 2016). Rice provides up to
one-half of the total caloric and protein intake to mil-
lions of hungry and poor people living in Asia. Rice is
also becoming an important staple food in Africa. Addi-
tionally, billions of people are engaged in the global rice
value chain for their employment as well as their liveli-
hood. Therefore, rice is crucial for global food and
nutritional security, and for alleviating rural poverty.
In the future, global rice security could be hampered
because of the following challenges that the world rice
sector is likely to encounter. First, population growth
could outpace rice production growth due to exhausting
the existing rice technologies, and indeed this has
already occurred (Nadarajah, 2016; Ray, Mueller, West,
& Foley, 2013). Therefore, the additional rice needed to
meet the demand from the growing population might
not be achieved. Second, a significant amount of land
currently under rice cultivation could be lost because of
rapid growth in urbanization, so the area under rice cul-
tivation is likely to shrink. Third, the global rice sector
could encounter frequent biotic stresses (e.g., pests and
diseases) and abiotic stresses (e.g., droughts and floods)
because of the erratic climatic behavior; therefore, sub-
stantial yield could be lost. Fourth, in some areas, irriga-
tion water could be unavailable for rice cultivation
because of overexploitation (e.g., this has already hap-
pened in Punjab, India). Finally, the demand for rice by
Africans is expected to increase in the future; therefore,
demand-led pressure on the global rice supply is likely
to rise.
To help solve these problems, rice scientists
invented C4 rice that could yield 50% more than current
rice with 40% less nitrogen and 50% less water (Sheehy
et al., 2007). The yield benefits could be realized only in
the irrigated rice areas, and the magnitudes of the bene-
fits could vary in the adopting countries. Using an
ORYZA model, a crop growth simulation model for
rice, Murty et al. (2016) estimated that the yield benefits
could be between 1% and 120% higher than those of
current rice, depending on the quality of the soil in the
adopting countries. If these yield advantages of C4 rice
could be realized in 13 Asian countries, then global rice
production would increase by 3% to 5% in 2050 com-
pared with the baseline values of 2050, estimated by
Bairagi, Mohanty, Murty, and Wiebe (2017) using a par-
tial equilibrium economic model (IMPACT).6 Because
of the increased rice supply, the global rice price could
decline by 9% to 14% in 2050; therefore, rice consump-
tion could increase by 3% to 5%. Finally, they found
that the number of people at risk of hunger and the num-
ber of malnourished children globally would decline by
1% to 2% and 0.5% to 0.8% in 2050, respectively. Thus,
we conclude that C4 rice could ensure future world food
and nutritional security through a sustained rice supply
under the challenging circumstances mentioned before.
Price of Innovation and Regulatory 
Approval Cost of C4 Rice
Because of the restricted policies related to intellectual
property rights (IPR) of IRRI, finding the detailed pro-
cesses and costs associated with the pre- and post-devel-
opment of a new GM rice (e.g., discovery and proof of
concept, introgression, breeding, and confined field tri-
Table 1. The roadmap to C4 rice.
Phases Commercial pathway of C4 rice
Initial time-
frame (IRRI, 
2012)
Tentative time-
frame (Sage, 
undated)
Our 
estimates
Phase I Gene discovery and molecular toolbox, and 
characterize regulatory controls
2009-2011 2009-2011 2009-2011
Phase II Transform rice to express Kranz anatomy 
and the C4 metabolic enzymes
2012-2014 2012-2015 2012-2015
Phase III Optimize C4 function in transgenic rice 2015-2019 2016-2020 2016-2022
Phase IV Breed C4 from transgenic into local 
varieties
2020-2023 2021-2025 2023-2028
Product prototype development 
(Phases I-IV) (years)
15 17 20
Post-development (years) 5 7
Commercialization 2030 2035
6. The International Model for Policy Analysis of Agricultural 
Commodities and Trade (IMPACT) was developed by the 
International Food Policy Research Institute (IFPRI).Bairagi & Mohanty — Compliance Costs for Regulatory Approval of C4 Rice
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challenging and almost impossible. Thus, the following
estimation of the price of innovation for C4 rice and
costs associated with its domestic regulatory approval is
based on personal communications of scientists and reg-
ulatory affairs officials of the Golden rice project at
IRRI, Philippines, and the available information pub-
lished in journal articles, books, and scientific reports.
The Roadmap to C4 Rice
As before, the development phases of C4 rice were
divided into four, presented in Table 1.7 At the begin-
ning of the C4 rice project, it is assumed that the proto-
type of C4 rice will be created within 15 years of starting
this project. However, based on the estimates by Rowan
F. Sage, professor of the University of Toronto, Phase
IV could be finished by 2025 and C4 rice could be com-
mercialized by 2035. We support Sage’s roadmap
because Phases III and IV usually take much more time,
which was the case for Golden rice. However, we have a
much more conservative estimate of about 20 years
(2028) required to obtain the product prototype. In addi-
tion, a total of seven years is likely to be required for C4
rice to be commercialized. For the whole period, 2009
to 2034, we estimated a total of $83.2 million (exclud-
ing indirect costs) to be required for investment in
research and development (R&D), including regulatory
approval cost, for C4 rice. This estimated R&D cost is
lower than the industry estimates by McDougall (2011),
who estimated a total of $136 million to be required by
any major biofortification company for development to
commercialization of any new GM product.
Costs Associated with Development Phases I-
III
IRRI started the C4 Rice Project with a grant of $11.0
million by BMGF for the first phase (Table 2). In Octo-
ber 2010, BMGF also granted $481 thousand to the
Shanghai Institute of Biological Sciences for this stage.
For the second phase, a total of $14.0 million was spent,
jointly funded by BMGF, the UK government, and
IRRI. Note that these first two phases were greatly
dependent on extensive genetic screening of rice plants,
led first by John Sheehy and then by Paul Quick from
IRRI. The third phase (2016 to 2019), emphasizing an
integrated “systems” approach and “synthetic” approach
to plant biology, is coordinated by Jane Langdale, pro-
fessor of the Department of Plant Sciences at the Uni-
versity of Oxford.8 This third phase of the project is also
being funded by BMGF, but at a level less than the first
two phases ($7.0 million).
Costs Associated with the Final Development 
Phase (Phase IV)
Recall that, at the beginning of the C4 Rice Project, the
cost of R&D was estimated at approximately $5.0 mil-
lion per year (IRRI, 2012). However, the amount spent
Table 2. Investment in C4 Rice Project globally.
Funder Grantee
Grant commission 
date
Grant amounts 
distributed
Duration of grant 
activities
Annually distributed 
($ million)
BMGF IRRI October 2008 $11,017,675 2009-2011 $3.67
BMGF Shanghai Institute of 
Biological Sciences
October 2010 $481,388 2010-2012 $0.16
BMGF * IRRI May 2012 $8,375,747 2013-2015 $2.79
The UK Govt. 
and IRRI †
IRRI - $5,624,253 2013-2015 $1.87
BMGF University of Oxford August 2015 $150,000 -
BMGF University of Oxford October 2015 $6,999,794 2016-2019 $1.75
Total $32,648,857 2009-2019 $3.00
Notes: Data were gathered from the different press releases of Bill & Melinda Gates Foundation (BMGF) and International Rice 
Research Institute (IRRI) websites.
*, † According to IRRI (2012), BMGF, the UK government, and IRRI jointly put $14.0 million into the second phase of the C4 Rice 
Project. To estimate the contribution by the UK government and IRRI, we deducted the BMGF contribution.
- denotes unknown.
7. Note that the technical aspects of the development phases of 
C4 rice can be found in Sheehy et al. (2000, 2007), Kajala et 
al. (2011), von Caemmerer, Quick, and Furbank (2012), 
Karki, Rizal, and Quick (2013), and Rizal et al. (2012). 8. Retrieved from https://c4rice.com/the-project-2/our-history/.Bairagi & Mohanty — Compliance Costs for Regulatory Approval of C4 Rice
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million annually (Table 2). In terms of average, approxi-
mately $3.0 million per year has been awarded thus far.
We assume that a similar amount will be required annu-
ally for Phase IV of the C4 Rice Project, amounting to
$18.0 million for 2023 to 2028 (Table 3).
Finally, after finishing Phase IV, the end product
would be a prototype of C4 rice. Based on the above
estimates, a total of $64.4 million is expected to be spent
for obtaining the prototype of C4 rice (discovery to
product development, Phases I to IV). Note that the esti-
mated costs are included only as direct R&D grants,
which may not reflect the actual amount of R&D to be
spent for this project. For example, a scientist who is
engaged in this project is also engaged in other activities
that are not linked to this project. So, the actual amount
of R&D investment in this project could be less than the
estimated amount. However, we argue that it also could
be more than the estimated R&D because many person-
nel are engaged in different universities and private
companies besides IRRI and its partner organizations in
the C4 Rice Project may be working on similar things.
Additionally, similar biofortification processes may be
conducted for different crops by several scientists glob-
ally. This must be taken into consideration in the cost
analysis. As this is unknown, we arbitrarily assumed
that the total cost of R&D, including the contribution of
universities and private companies, could be at least 1.5
times the estimated R&D, amounting to around $96.6
million (= 64.4×1.5).
Compliance Cost for Approval of C4 Rice
In the literature, studies related to quantifying the com-
pliance costs for approval of a GM crop are very limited
and none of the studies reported actual regulatory
approval cost estimates. The reason could be that this is
a very sensitive issue that biotech companies do not
want to share or because of IPR-related restrictions. A
recent study by Smyth et al. (2017), most probably the
only rigorous study in this field, quantified the regula-
tory approval costs using a meta-analysis method. This
study found that the average cost of regulatory compli-
ance for a single new trait in a single market is around
$7.8 million. We argue that their estimates could be
somewhat overestimated, based on the following ratio-
nale.
Figure 1 illustrates the regulatory approval costs for
GM crops, adopted from Smyth et al. (2017).9 Note that
there is a debate about whether a particular activity is a
component of compliance cost or a product develop-
ment cost (Falck-Zepeda et al., 2007). This figure
clearly depicts that compliance costs of approval for a
GM crop diverge whether it is a food or non-food crop.
Among the food crops, compliance costs for GM maize
differ significantly from those for rice and other edible
crops. Note that, if the compliance costs of GM maize
Table 3. Estimated R&D costs required to develop C4 rice.
Research, development, breeding, trials, and regulatory 
phases
Estimated R&D for C4 rice
Required time 
(year)
Per-year required R&D 
($ million)
Total required R&D 
($ million)
Phase I ^ 3.0 $3.8 $11.4
Phase II ^ 4.0 $3.5 $14.0
Phase III 7.0 $3.0 $21.0
Phase IV 6.0 $3.0 $18.0
Subtotal (Phases I-IV) 20.0 $3.2 $64.4
Subtotal (Phases I-IV), including universities and private 
companies spending unseen**
(64.4 × 1.5) = $96.6
Regulatory process* 7.0 $18.8
Total 27.0 $115.4
Notes:
^ from Table 2
* estimated for 13 Asian countries, so the simulated mean (1.44 in Figure 2) was multiplied by the total number of C4 rice-adopting 
countries
** arbitrarily assumed the spending by the universities and private companies for developing C4 rice to be 1.5 times
9. This study cited Pray et al. (2005, 2006), Falck-Zepeda et al. 
(2007), Falck-Zepeda and Cohen (2006), Kalaitzandonakes et 
al. (2007), and Bayer, Norton, and Falck-Zepeda (2010). In 
addition, we included Ramaswami and Pray (2006), Stein et 
al. (2008), and Chow et al. (2010) in the analysis.Bairagi & Mohanty — Compliance Costs for Regulatory Approval of C4 Rice
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(2007) were excluded, then the average approval cost of
GM maize would have been similar to the approval cost
of GM rice. If Smyth et al. (2017) could have estimated
the regulatory approval cost without this study, then
their number would have been significantly lower. Note
also that Kalaitzandonakes et al. (2007) estimated a
compliance cost incurred by the biotech developers
seeking regulatory approval of two GM maize lines in
10 key producing and importing countries in the world
at about $6-15 million. This estimate could be correct
based on the fact that they considered that the biotech
company will be seeking approval of its GM maize in
10 countries. However, their number is almost one-half
the estimates by McDougall (2011), who estimated the
regulatory approval cost of a new GM crop to be around
$35 million. Note that his estimation was based on
whether the new GM crop “had received cultivation
approval in two countries and import approvals from at
least five countries” and whether a private company had
filed for approval.
From the above discussion, two important points can
be noted: (i) regulatory approval costs could vary signif-
icantly based on the number of countries in which the
biotech developers are seeking approval for cultivation
and importation of a GM crop, and (ii) the costs could
also vary based on whether private or public companies
are seeking approval. These are the two key facts that
were ignored by Smyth et al. (2017); thus, their numbers
could be overestimated. For example, if a private bio-
tech company is seeking approval of its newly devel-
oped GM crop in 10 countries (some cultivating and
importing countries), then approval costs could surpass
$50 million (10 multiplied by the average cost esti-
mates, for example). Therefore, rather than adopting the
average number estimated by Smyth et al. (2017), we
followed a straight-forward strategy to estimate the
compliance costs for approval of C4 rice to be adopted
in 13 Asian countries.
Table 4 presents the country-specific compliance
costs for regulatory approval of GM rice developed thus
far. We find that the costs vary between $73 thousand in
Indonesia and $4.0 million in India. Table 4 also reveals
that, for Golden rice, the costs are much higher than the
mean regulatory cost. In the Philippines, they are around
$137 thousand, but $2.2 to 4.0 million for India. Note
that the major shares of this cost accrue from the toxic-
ity tests (animal, food, and environmental safety stud-
ied) and regulated confined trials and unregulated trials.
In the case of C4 rice, we argue that the cost for approval
in a single market could be similar to that of Golden rice
in India. Although this depends on whether any further
toxicity tests done in the United States or EU are to be
required by the country-specific government. Because
the biosafety procedures in Bangladesh, India, and the
Philippines are similar, further toxicity tests are unlikely
to be required. In that case, on the whole, the compli-
ance costs for approval of C4 rice in 13 Asian countries
could be lower.
Based on the personal communications of IRRI sci-
entists, the compliance costs for approval of Golden rice
for the three countries could be $6.0-8.0 million. We
argue that the compliance costs for C4 rice could par-
tially depend on the effect of Golden rice on humans and
the environment. For example, by the time of C4 com-
mercialization, the impact of Golden rice on human life
and environmental health could be realized. If no nega-
tive impact on humans and the environment is found,
then biosafety regulation could be faster, easier, and
more cost-effective for C4 rice. Furthermore, the current
technology, for example, CRISPR/Cas9 used for target
gene editing, is much more advanced than the technol-
ogy available when the C4 Rice Project started. With the
new advanced technology, the targeted rice gene could
be edited to have C4 function and thus the new C4 rice
plant would not be considered transgenic in some coun-
tries.
Figure 1. Regulatory approval costs for GM crops.
Source: Authors’ data computed from data reported in Tables 
3.4 and 3.5 in Smyth et al. (2017), where Pray et al. (2005, 
2006), Falck-Zepeda et al. (2007), Falck-Zepeda and Cohen 
(2006), Kalaitzandonakes et al. (2007), and Bayer et al. (2010) 
were cited. In addition, we included Ramaswami and Pray 
(2006), Stein, Sachdev, and Qaim (2008), Chow, Klein, and 
Laxminarayan (2010), and Falck-Zepeda, Gruère, and Sithole-
Niang (2013).
Notes: Other edible crops include banana, beans, eggplant, 
mustard, papaya, potatoes, soybeans, sugarcane, tomato, and 
vegetable; non-food crops include cotton and jute.Bairagi & Mohanty — Compliance Costs for Regulatory Approval of C4 Rice
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cost of approximately $18.8 million employing a Bayes-
ian simulation method. We used only the reported coun-
try-specific compliance costs for regulatory approval of
GM rice in Table 4 along with other food crops in Fig-
ure 1. We assumed a normally distributed likelihood
function along with a prior mean and standard deviation
adopted from Smyth et al. (2017). Figure 2 illustrates
the simulated results, which reveal that the posterior
mean compliance cost is $1.44 million. We multiply this
mean compliance cost by the number of C4 adopting
countries, and find that the regulatory compliance costs
for approval of C4 rice could be $18.8 million, which
are around 16.3% of the total R&D costs required for C4
rice.
Present Value of Innovation and 
Compliance Costs
In this article, we also estimated the present value of
innovation and compliance costs in 2017 prices. To con-
vert these costs to the current price, we compounded
them from 2009 to 2016 and discounted them from 2018
to 2035, with a 10% discount rate. This discount rate
considered here is slightly high because potential risks
are involved in the C4 innovation process. Note that, in
the global perspective, developing countries tend to use
higher discount rates (above 10%) than developed coun-
tries (Bairagi, 2015).10 We found that the present value
of innovation and compliance costs for approval of C4
rice in the 13 countries was approximately $106 million.
In sum, our estimated R&D costs could be useful to
quantify the net welfare benefits from the introduction
of C4 rice. In addition, donors could use this result as a
guideline to fund the additional investment required for
developing C4 rice. However, this should be used with
caution because the estimates are backed by neither any
actual estimates nor any rigorous econometric methods.
Table 4. Country-specific cost of compliance for regulatory approval of GM rice.
GM rice Countries
Regulatory cost ($ ‘000) No. of countries 
seeking approval SourceMin Max
Golden rice India 2,213 2,515 1 Stein, Sachdev, & Qaim (2006)
Golden rice India 4,000 Ramaswami and Pray (2006)
Rice India 1,500 2,000 1 Pray et al. (2005)
Golden rice Philippines 134 1 Falck-Zepeda et al. (2007)
Xa21 BBR rice Philippines 128 1 Falck-Zepeda et al. (2007)
Bt rice Philippines 691 1 Bayer et al. (2010)
Bt rice Indonesia 73 1 Falck-Zepeda et al. (2007)
Bt rice Costa Rica 2,800 1 Falck-Zepeda and Cohen (2006)
Virus-resistant rice Costa Rica 680 1 Sittenfeld (2002) cited in Falck-Zepeda 
and Cohen (2006)
Average 1,358 1,447
Notes: Bt denotes insect resistance; BBR stands for bacterial blight resistant. Golden rice is a beta-carotene (SGR1)-enriched GM 
rice.
10. Discount rates used by the different developed and developing 
countries can be found in Harrison (2010).
Figure 2. Simulated compliance cost for C4 rice in a single 
market.
Source: Authors’ computation based on only compliance cost of 
food crops reported in Tables 3.4 and 3.5 in Smyth et al. (2017), 
where Pray et al. (2005, 2006), Falck-Zepeda et al. (2006), 
Falck-Zepeda and Cohen (2006), and Bayer et al. (2010) were 
cited. In addition, we included Ramaswami and Pray (2006), 
Stein et al. (2008), Chow et al. (2010), and Falck-Zepeda et al. 
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This article estimates R&D costs, including a regulatory
cost, for approval of C4 rice to be adopted in 13 Asian
countries. Most new biotech crops have been developed
thus far by transforming one or two genes with preferred
traits, whereas, to develop a C4 rice plant, several genes
would need to be transformed. It is unknown in the liter-
ature whether a new biotech crop with multiple trans-
formed genes would cost significantly more and take
much more time to be approved. In this article, we esti-
mate the price of innovation for C4 rice and the costs
associated with its domestic regulatory approval based
on the personal communications of scientists and regu-
latory affairs officials of the Golden rice project at IRRI,
Philippines, and the available information published in
journal articles, books, and scientific reports. We
assume that the prototype of C4 rice could be created by
2028 and C4 rice would be commercialized in 2035. We
also assume that the regulatory process would begin
simultaneously after obtaining the prototype. We find
that the estimated compliance costs for the regulatory
approval of C4 rice in a single market would be approxi-
mately $1.44 million. For the 13 adopting countries, the
regulatory cost was estimated to be around $18.8 mil-
lion (undiscounted), which is 16.3% of the total R&D
costs required for C4 rice. It is expected that the regula-
tory process would finish within seven years. Finally,
we estimated a present value of innovation and compli-
ance costs for approval of C4 rice in the 13 countries at
approximately $106 million.
In this article, we argue that the compliance costs for
C4 rice could depend somewhat on the effect of Golden
rice on humans and the environment. It is expected that
the impact of Golden rice on human life and environ-
mental health could be realized by the time of C4 com-
mercialization. If no negative impact on humans and the
environment is found, then biosafety regulation could be
faster, easier, and more cost-effective for C4 rice. Fur-
thermore, the current technology, for example, CRISPR/
Cas9 used for target gene editing, is much more
advanced than the technology available when the C4
Rice Project started. With the new advanced technology,
the targeted rice gene could be edited to have C4 func-
tion and thus the new C4 rice plant would not be consid-
ered transgenic in some countries. Therefore, the
regulatory process could be easier and faster, resulting
in lower regulatory costs and less time required to be
commercialized.
We believe that our estimated R&D costs could be
useful to quantify the net welfare benefits from the
introduction of C4 rice. In addition, donors could use
this result as a guideline to fund the additional invest-
ment required for developing C4 rice.
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